Iwao Ojima

Port Jefferson, NY, United States of America

Iwao Ojima

USPTO Granted Patents = 31 

 

Average Co-Inventor Count = 2.1

ph-index = 4

Forward Citations = 143(Granted Patents)


Company Filing History:


Years Active: 2001-2025

Loading Chart...
Loading Chart...
31 patents (USPTO):Explore Patents

Title: The Inventor Extraordinaire: Iwao Ojima

Introduction:

Meet Iwao Ojima, a prolific inventor based in Port Jefferson, NY, with an impressive track record of 27 patents to his name. His innovative work in the field of anti-fungal compounds and pharmaceutical compositions has made a significant impact in the scientific community.

Latest Patents:

Ojima's latest patents include groundbreaking inventions such as anti-fungal compounds targeting the synthesis of fungal sphingolipids, and Alpha-truxillic acid derivatives with pharmaceutical applications. These patents showcase his dedication to developing novel solutions for combating fungal infections and advancing the field of medicine.

Career Highlights:

Throughout his career, Ojima has made significant contributions to various research institutions, including The Research Foundation for the State University of New York and The Research Foundation of the State University of New York. His expertise and groundbreaking inventions have positioned him as a leading figure in the pharmaceutical and biotechnology industries.

Collaborations:

Ojima has collaborated with esteemed professionals in the field, including coworkers Dale Deutsch and Martin Kaczocha. These collaborations have not only enhanced his innovative work but have also paved the way for future research and development initiatives in the industry.

Conclusion:

In conclusion, Iwao Ojima's inventive prowess and dedication to scientific advancements have solidified his reputation as an inventor extraordinaire. His relentless pursuit of developing cutting-edge solutions in the realm of anti-fungal compounds and pharmaceutical compositions continues to inspire and drive innovation in the scientific community.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…